About Potassium channel subfamily K member 5
Potassium channel subfamily K member 5 (KCNK5) is a protein
from Homo sapiens identified by UniProt accession
O95279, 499 residues long.
MolForge cross-references it against 0 known binders and
135 disease associations.
Target properties
| Protein name | Potassium channel subfamily K member 5 |
| UniProt accession | O95279 |
| Gene | KCNK5 |
| Organism | Homo sapiens |
| Length | 499 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (135)
Diseases linked to this target (Open Targets).
- coronary artery disease · score 0.47
- diastolic blood pressure · score 0.46
- migraine disorder · score 0.43
- body height · score 0.43
- hemoglobin measurement · score 0.43
- appendicular lean mass · score 0.41
- hematocrit · score 0.41
- myocardial infarction · score 0.40
- erythrocyte count · score 0.40
- hypertension · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95279-F1 | alphafold | PREDICTED | 68.95 | — |
Amino-acid sequence (499 residues)
MVDRGPLLTS AIIFYLAIGA AIFEVLEEPH WKEAKKNYYT QKLHLLKEFP CLGQEGLDKI LEVVSDAAGQ GVAITGNQTF NNWNWPNAMI FAATVITTIG YGNVAPKTPA GRLFCVFYGL FGVPLCLTWI SALGKFFGGR AKRLGQFLTK RGVSLRKAQI TCTVIFIVWG VLVHLVIPPF VFMVTEGWNY IEGLYYSFIT ISTIGFGDFV AGVNPSANYH ALYRYFVELW IYLGLAWLSL FVNWKVSMFV EVHKAIKKRR RRRKESFESS PHSRKALQVK GSTASKDVNI FSFLSKKEET YNDLIKQIGK KAMKTSGGGE TGPGPGLGPQ GGGLPALPPS LVPLVVYSKN RVPTLEEVSQ TLRSKGHVSR SPDEEAVARA PEDSSPAPEV FMNQLDRISE ECEPWDAQDY HPLIFQDASI TFVNTEAGLS DEETSKSSLE DNLAGEESPQ QGAEAKAPLN MGEFPSSSES TFTSTESELS VPYEQLMNEY NKANSPKGT
Explore Potassium channel subfamily K member 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets